Science & Enterprise subscription

Follow us on Twitter

  • Industrial Policy Isn’t Boring. It’s Big, and It Has United the Left and Right. https://t.co/HVRDGJRBPd
    about 34 mins ago
  • A company making synthetic biological therapies received authorization to begin clinical trials in the U.S. for an… https://t.co/TXPkxYXMtW
    about 16 hours ago
  • New post on Science and Enterprise: FDA Okays Celiac Disease Engineered Microbe Trial https://t.co/myw378pGLy #Science #Business
    about 16 hours ago
  • An enterprise supporting a group of companies developing new drugs to address the aging process raised another $100… https://t.co/P2L8KpysFV
    about 20 hours ago
  • New post on Science and Enterprise: Aging Therapy Network Adds $100M to Venture Round https://t.co/MhaYWDrJVq #Science #Business
    about 20 hours ago

Please share Science & Enterprise

Infographic – Superbugs Annually Kill 33,000 in Europe

Chart: Superbug deaths n Europe

Click on image for full-size view. (The Lancet, Statista)

10 Nov. 2018. We’ve reported at Science & Enterprise on the problem of antibiotic resistance for several years. Bacteria and viruses evolve into new strains resistant to current antibiotics, also known as “superbugs,” causing health authorities and drug developers to scramble for stronger or alternative options. In some cases, authorities are concerned the development of new antibiotics can’t keep up with new superbug strains, with ominous implications for public health.

Our friends at Statista posted a chart this week that underscores this problem, showing the median number of deaths by country in Europe from microbes resistant to antibiotics, this weekend’s infographic. The data from 2015 first appeared in a paper earlier this month in the medical journal The Lancet, showing some 33,000 died from antibiotic-resistant infections that year. About one-third of those deaths, nearly 11,000, occurred in Italy, with another 5,500 in France.

Researchers on both sides of the Atlantic seem to be taking this threat seriously, and we’ve reported in Science & Enterprise on advances in academic and industry labs to develop new or more powerful diagnostics and antibiotics. A few of the most recent stories are listed below.

More from Science & Enterprise:

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.